Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: Implications for prognosis and disease biology

International Journal of Laboratory Hematology

Volumn 32, Issue 1 PART.2, 2010, Pages 95-102

  Ma, W ^a   Kantarjian, H ^b   Zhang, X ^a   Yeh, C H ^a   Zhang, Z J ^a   Verstovsek, S ^b   O'Brien, S ^b   Giles, F ^c   Albitar, M ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c University of Texas Health Science Center at San Antonio   (United States)

Author keywords

Essential thrombocythemia; Exon 12; Idiopathic myelofibrosis; JAK2; Mutation; Plasma; Polycythemia vera

Indexed keywords

JANUS KINASE 2; MESSENGER RNA; MUTANT PROTEIN; PROTEIN V617F; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MYELOPROLIFERATIVE DISORDER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SURVIVAL RATE; TREATMENT INDICATION;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS; RNA, MESSENGER;

EID: 77449155987     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2009.01140.x     Document Type: Article

References (17)

1. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., Scott M.A., Erber W.N. & Green A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061.
2. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., Garçon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N. & Vainchenker W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148. (Pubitemid 40663494)
3. Jones A.V., Kreil S., Zoi K., Waghorn K., Curtis C., Zhang L., Score J., Seear R., Chase A.J., Grand F.H., White H., Zoi C., Loukopoulos D., Terpos E., Vervessou E.C., Schultheis B., Emig M., Ernst T., Lengfelder E., Hehlmann R., Hochhaus A., Oscier D., Silver R.T., Reiter A. & Cross N.C. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106, 2162-2168.
4. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M. & Skoda R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine 352, 1779-1790. (Pubitemid 40570926)
5. Levine R.L., Wadleigh M., Cools J. Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., Adelsperger J., Koo S., Lee J.C., Gabriel S., Mercher T., D'Andrea A., Fröhling S., Döhner K., Marynen P., Vandenberghe P., Mesa R.A., Tefferi A., Griffin J.D., Eck M.J., Sellers W.R., Meyerson M., Golub T.R., Lee S.J. & Gilliland D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397.
6. Ma W., Kantarjian H., Verstovsek S., Jilani I., Gorre M., Giles F., Cortes J., O'Brien S., Keating M. & Albitar M. (2006) Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: Correlation with clinical behaviour. British Journal of Haematology 134, 341-343.
7. Ma W., Tseng R., Gorre M., Jilani I., Keating M., Kantarjian H., Cortes J., O'Brien S., Giles F. & Albitar M. (2007) Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukaemia. Haematologica 92, 170-175.
8. Ma W., Kantarjian H., Zhang X., Sun W., Buller A.M., Jilani I., Schwartz J.G., Giles F. & Albitar M. (2008) Higher detection rate of JAK2 mutation using plasma. Blood 111, 3906-3907.
9. Manshouri T., Do K.A., Wang X. Giles F.J., O'Brien S.M., Saffer H., Thomas D., Jilani I., Kantarjian H.M., Keating M.J. & Albitar M., Cervantes F., Hernández-Boluda J.C. & Bellosillo B. (2003) Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukaemia and is of prognostic significance. Blood 101, 2507-2513.
10. Martínez-Avilés L., Besses C., Alvarez-Larrán A., Cervantes F., Hernández-Boluda J.C. & Bellosillo B. (2007) JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis. Haematologica 92, 1717-1718.
11. Nelson M.E. & Steensma D.P. (2006) JAK2 V617F in myeloid disorders: What do we know now, and where are we headed? Leukemia & Lymphoma 47, 177-194.
12. Pardanani A., Lasho T.L., Finke C., Hanson C.A. & Tefferi A. (2007) Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 21, 1960-1963.
13. Rogers A., Joe Y., Manshouri T., Dey A., Jilani I., Giles F., Estey E., Freireich E., Keating M., Kantarjian H. & Albitar M. (2004) Relative increase in leukaemiaspecific DNA in peripheral blood plasma from patients with acute myeloid leukaemia and myelodysplasia. Blood 103, 2799-2801.
14. Schindler C.W. (2002) JAK-STAT signaling in human disease. Journal of Clinical Investigation 109, 1133-1137.
15. Scott L.M., Tong W., Levine R.L., Scott M.A., Beer P.A., Stratton M.R., Futreal P.A., Erber W.N., McMullin M.F., Harrison C.N., Warren A.J., Gilliland D.G., Lodish H.F. & Green A.R. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. New England Journal of Medicine 356, 459-468.
16. Steensma D.P., Dewald G.W., Lasho T.L., Powell H.L., McClure R.F., Levine R.L., Gilliland D.G. & Tefferi A. (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 106, 1207-1209.
17. Zhao R., Xing S., Li Z., Fu X., Li Q., Krantz S.B. & Zhao Z.J. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. Journal of Biological Chemistry 280, 22788-22792.